Referrals to the Genentech BioOncology Co-pay Card
Co-pay card programs provide direct financial assistance to patients to help with their co-pays, co-insurance or other out-of-pocket costs. If eligible commercially insured patients need assistance with their out-of-pocket costs, Genentech BioOncology® Access Solutions for COTELLIC and ZELBORAF can refer them to the Genentech BioOncology Co-pay Card.
To get started, call (855) MYCOPAY (855-692-6729) or visit CopayAssistanceNow.com.
The Genentech BioOncology Co-pay Card is available only for
commercially insured patients. Patients using Medicare, Medicaid,
Medigap, Veteran's Affairs (VA), Department of Defense (DoD),
TriCare or any other government-funded program to pay for their
medications are not eligible. Patients who start utilizing their
government coverage during their enrollment period will no longer be
eligible for the program. It requires a valid, on-label prescription
and cannot be combined with any other rebate/coupon, free trial or
similar offer for the specified prescription. It is available only
for a patient (or their guardian) who is 18 years or older. It is
not valid for medications the patient receives for free or that are
eligible to be reimbursed by private insurance plans or other health
care or pharmaceutical assistance programs that reimburse the
patient in whole or in part for the medication. It is valid only for
Genentech products in the United States and US Territories. The
Genentech BioOncology Co-pay Card is not health insurance or a
benefit plan. Please see full terms and conditions at CopayAssistanceNow.com.
Important Safety Information & Indication
Indications and Usage
COTELLIC (cobimetinib) is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with ZELBORAF (vemurafenib).
Important Safety Information
WARNINGS AND PRECAUTIONS
Review the Full Prescribing Information for ZELBORAF for information on the serious risks of ZELBORAF.
The following can occur in patients treated with COTELLIC:
- New primary malignancies, including cutaneous and non-cutaneous malignancies
- Hemorrhage, including major hemorrhages
- Cardiomyopathy, defined as symptomatic and asymptomatic decline in left ventricular ejection fraction
- Severe dermatologic reactions, including rash and other skin reactions
- Serous retinopathy and retinal vein occlusion
- Severe photosensitivity
- Embryo-fetal toxicity
The following can occur in patients treated with ZELBORAF:
- New primary malignancies including cutaneous squamous cell carcinoma, non-cutaneous squamous cell carcinoma, new primary melanoma, and other malignancies
- Tumor promotion in BRAF wild-type melanomas
- Serious hypersensitivity reactions including anaphylaxis
- Severe dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
- QT prolongation
- Hepatotoxicity including liver injury leading to functional hepatic impairment (including coagulopathy or other organ dysfunction); increases in transaminases and bilirubin when concurrently administered with ipilimumab
- Ophthalmologic reactions, including uveitis, blurry vision, and photophobia
- Embryo-fetal toxicity
- Radiation sensitization and radiation recall, including fatal cases in patients with visceral involvement
- Renal failure, including acute interstitial nephritis and acute tubular necrosis
- Dupuytren’s contracture and plantar fascial fibromatosis
USE IN SPECIFIC POPULATIONS: Lactation
Advise women not to breastfeed during treatment with COTELLIC and ZELBORAF and for 2 weeks after the final dose of COTELLIC or ZELBORAF (whichever is taken later).
- Avoid concomitant administration of COTELLIC with strong or moderate CYP3A inducers or inhibitors.
- Avoid concurrent use of ZELBORAF with strong CYP3A4 inhibitors, strong CYP3A4 inducers, and CYP1A2 and P-glycoprotein substrates with narrow therapeutic windows.
Most Common Adverse Reactions
The most common (≥20%) adverse reactions with COTELLIC were diarrhea (60%), photosensitivity reaction (46%), nausea (41%), pyrexia (28%), and vomiting (24%). The most common (≥5%) Grade 3-4 laboratory abnormalities were increased GGT (21%), increased CPK (14%), hypophosphatemia (12%), increased ALT (11%), lymphopenia (10%), increased AST (8%), increased alkaline phosphatase (7%), and hyponatremia (6%).
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.